Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Gemcitabine-resistant pancreatic cancer: a second-line option

In The Lancet, Andrea Wang-Gillam and colleagues1 report on a randomised phase 3 trial (NAPOLI-1) in 417 patients with metastatic gemcitabine-resistant pancreatic cancer. The primary endpoint of overall survival was improved significantly with the combination of nanoliposomal irinotecan plus fluorouracil and folinic acid when compared with a control of fluorouracil and folinic acid (6·1 months [95% CI 4·8–8·9] vs 4·2 months [3·3–5·3]; hazard ratio [HR] 0·67, 95% CI 0·49–0·92). Subgroup analyses consistently favoured the combination treatment, further supporting a robust treatment effect on overall survival.

email